MX2021013106A - Composicion de naproxeno en minicapsulas de gel blando. - Google Patents

Composicion de naproxeno en minicapsulas de gel blando.

Info

Publication number
MX2021013106A
MX2021013106A MX2021013106A MX2021013106A MX2021013106A MX 2021013106 A MX2021013106 A MX 2021013106A MX 2021013106 A MX2021013106 A MX 2021013106A MX 2021013106 A MX2021013106 A MX 2021013106A MX 2021013106 A MX2021013106 A MX 2021013106A
Authority
MX
Mexico
Prior art keywords
mini
softgel
softgel capsules
naproxen
disclosed
Prior art date
Application number
MX2021013106A
Other languages
English (en)
Inventor
Rickey Steve Shelley
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of MX2021013106A publication Critical patent/MX2021013106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Abstract

En este documento se dan a conocer minicápsulas de gel blando que comprenden un producto de reacción de ácido libre de naproxeno e hidróxido de potasio en una relación molar de hidróxido de potasio a ácido libre de naproxeno de menos de aproximadamente 1. En este documento también se dan a conocer métodos para tratar pacientes, en necesidad de ello, con las minicápsulas de gel blando, así como métodos para estabilizar minicápsulas de gel blando que incluyen una composición de relleno que tiene una alta concentración de agente activo.
MX2021013106A 2019-04-26 2020-04-22 Composicion de naproxeno en minicapsulas de gel blando. MX2021013106A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839198P 2019-04-26 2019-04-26
PCT/US2020/029234 WO2020219499A1 (en) 2019-04-26 2020-04-22 Mini softgel naproxen composition

Publications (1)

Publication Number Publication Date
MX2021013106A true MX2021013106A (es) 2022-01-24

Family

ID=72941368

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013106A MX2021013106A (es) 2019-04-26 2020-04-22 Composicion de naproxeno en minicapsulas de gel blando.

Country Status (14)

Country Link
US (1) US20220202751A1 (es)
EP (1) EP3958852A4 (es)
JP (1) JP2022530468A (es)
KR (1) KR20220004691A (es)
CN (1) CN113950324A (es)
AR (1) AR118790A1 (es)
AU (1) AU2020263295A1 (es)
BR (1) BR112021021414A2 (es)
CA (1) CA3138131A1 (es)
CO (1) CO2021015117A2 (es)
IL (1) IL287590A (es)
MX (1) MX2021013106A (es)
TW (1) TW202106291A (es)
WO (1) WO2020219499A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117677379A (zh) * 2021-07-06 2024-03-08 R·P·谢勒技术有限公司 软胶囊
CN115887407B (zh) * 2022-12-29 2023-08-18 深圳市泰力生物医药有限公司 一种西罗莫司软胶囊及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071643A (en) * 1986-10-17 1991-12-10 R. P. Scherer Corporation Solvent system enhancing the solubility of pharmaceuticals for encapsulation
US6387400B1 (en) * 2000-08-29 2002-05-14 R.P. Scherer Technologies, Inc. Process for preparing pharmaceutical compositions for use with soft gelatin formulations
US6689382B2 (en) * 2002-05-15 2004-02-10 Procaps S.A. Soft shell gelatin capsules containing non-steroidal anti-inflammatories
US20070053868A1 (en) * 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof

Also Published As

Publication number Publication date
WO2020219499A1 (en) 2020-10-29
AR118790A1 (es) 2021-11-03
TW202106291A (zh) 2021-02-16
EP3958852A1 (en) 2022-03-02
BR112021021414A2 (pt) 2022-02-15
JP2022530468A (ja) 2022-06-29
KR20220004691A (ko) 2022-01-11
CA3138131A1 (en) 2020-10-29
EP3958852A4 (en) 2023-01-18
US20220202751A1 (en) 2022-06-30
AU2020263295A1 (en) 2021-11-18
CO2021015117A2 (es) 2021-11-19
CN113950324A (zh) 2022-01-18
IL287590A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
WO2016135557A3 (en) Materials and methods for treatment of hemoglobinopathies
WO2017077394A3 (en) Materials and methods for treatment of hemoglobinopathies
WO2016135559A3 (en) Materials and methods for treatment of human genetic diseases including hemoglobinopathies
MX2021013106A (es) Composicion de naproxeno en minicapsulas de gel blando.
MX361430B (es) Una composición para el cuidado oral que comprende un carbonato de calcio tratado mediante reacción superficial.
PH12016500164A1 (en) Therapeutically active compounds and their methods of use
IN2012DN06581A (es)
UA115532C2 (uk) Модулятори нуклеарного транспорту, що містять гідразид, і їхнє застосування
PH12015502542A1 (en) Stabilized pemetrexed formulation
MX363512B (es) Proceso de glicoconjugacion.
CL2011002432A1 (es) Composicion que comprende al menos una enzima digestiva y al menos un portador, en donde el portador comprende celulosa microcristalina que tiene un tamaño de particulas mayor que 100 um; una forma de dosificacion; el envase que la contiene; un proceso para preparar la composicion; y sus usos.
PH12015501126B1 (en) Peroxide-stable oral care compositions
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
PH12015501375A1 (en) Stable metal ion containing compositions
MX2016013154A (es) Composicion que contiene peroxido y acido peracetico y proceso para matar esporas.
MX2015017854A (es) Composicion que comprende glutamico-n, n-diacetato (glda), agua y enzima.
PH12016502418A1 (en) Recuronium preparation with improved stability
PH12016501554A1 (en) Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
AR087371A1 (es) Formulaciones de (trimetoxifenilamino)pirimidinilo, metodos
IN2012DN02126A (es)
MX2018000940A (es) Formulaciones efervescentes de aspartato de ornitina.
MX2023000198A (es) Inhibidores de atr y usos de estos.
MX2022003997A (es) Derivados de androstano con actividad como estimuladores puros o predominantemente puros de serca2a para el tratamiento de la insuficiencia cardiaca.
MX2021015732A (es) Administracion intranasal de merotocina para mejorar la lactancia.
IN2014MU00486A (es)